INDV

Peers: ALKS AMRX EBS SUPN COLL NBIX PCRX AQST ACAD HRMY

Index	-
Market Cap	5.43B
Enterprise Value	5.63B
Income	450.00M
Sales	1.37B
Book/sh	-0.51
Cash/sh	1.58
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Nov 03, 2026
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	838
IPO	Dec 29, 2014

P/E	7.79
Forward P/E	6.93
PEG	0.31
P/S	3.95
P/B	-
P/C	17.82
P/FCF	209.32
EV/EBITDA	8.89
EV/Sales	4.10
Quick Ratio	0.50
Current Ratio	0.62
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / No

EPS (ttm)	3.61
EPS next Y	4.06
EPS next Q	0.93
EPS this Y	34.55%
EPS next Y	20.78%
EPS next 5Y	22.42%
EPS past 3/5Y	- -
Sales past 3/5Y	11.20% 13.88%
EPS Y/Y TTM	265.06%
Sales Y/Y TTM	16.44%
EPS Q/Q	244.87%
Sales Q/Q	13.38%
Earnings	Oct 29 BMO
EPS/Sales Surpr.	24.45% 8.09%

Insider Own	3.00%
Insider Trans	-1.17%
Inst Own	96.84%
Inst Trans	-8.86%
ROA	32.75%
ROE	-
ROIC	-
Gross Margin	85.08%
Oper. Margin	45.05%
Profit Margin	32.75%
SMA20	3.78%
SMA50	3.11%
SMA200	1.68%
Trades

Shs Outstand	124.77M
Shs Float	121.03M
Short Float	7.78%
Short Ratio	2.94
Short Interest	9.41M
52W High	33.22 -15.25%
52W Low	21.48 31.07%
Volatility	4.60% 3.65%
ATR (14)	0.98
RSI (14)	58.42
Beta	1.12
Rel Volume	0.00
Avg Volume	3.21M
Volume	0

Perf Week	2.57%
Perf Month	2.34%
Perf Quarter	-5.69%
Perf Half Y	-8.15%
Perf YTD	1.11%
Perf Year	23.53%
Perf 3Y	82.86%
Perf 5Y	115.31%
Perf 10Y	66.04%
Recom	1.25
Target Price	47.75
Prev Close	28.15
Price	28.15
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$47.75

Implied Upside

+69.6%

Analysts7incl. previous ratings

Rating Distribution7 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 18, 2026	Initiated	BBarclays	Overweight	$46	+63.4%
Aug 06, 2025	Initiated	HH.C. Wainwright	Buy	$27	-4.1%
Jul 22, 2025	Resumed	JJefferies	Buy	$20	-29.0%
Jan 28, 2025	Initiated	RRodman & Renshaw	Buy	$16	-43.2%
Jul 23, 2024	Initiated	PPiper Sandler	Overweight	$22	-21.8%
Apr 03, 2024	Initiated	CCraig Hallum	Buy	$37	+31.4%
Jul 13, 2023	Initiated	NNorthland Capital	Outperform	$35	+24.3%

Oct-29-26 07:00AM	Indivior Reports Third Quarter 2026 Financial Results (GlobeNewswire)
Oct-28-26 05:43PM	Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600 (PR Newswire)
Oct-22-26 06:08PM	MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600 (PR Newswire)
Oct-21-26 01:03PM	Indivior Heads Into Q3 With Street Estimates Trailing Its Raised Revenue Outlook (Earnings Whispers)
Oct-19-26 08:30AM	Indivior to Report Third Quarter 2026 Financial Results (GlobeNewswire)
01:53PM	Loading…
Sep-29-26 01:53PM	Are LFCR, ITGR, FHB, INDV Obtaining Fair Deals for their Shareholders? (PR Newswire)
Sep-17-26 07:00AM	Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend (GlobeNewswire)
Aug-03-26 08:47AM	Indivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook (InvestorsHub) -6.60%
08:28AM	Supernus Shares Jump After Revenue Beat, Higher Guidance and Indivior Merger Announcement (InvestorsHub)
08:22AM	Supernus jumps premarket on merger deal; GameStop drops (Investing.com)
06:31AM	Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance (GlobeNewswire)
Jul-31-26 12:44PM	This Pharma Stock Eyes Entry As Opioid Addiction Specialist's Profits Surge 108% (Investor's Business Daily)
Jul-23-26 10:00AM	Indivior to Report Second Quarter 2026 Financial Results and Host Webcast (GlobeNewswire)
Jun-25-26 11:27AM	IBD 50 Stock Indivior Breaks Out Amid Big Fund Ownership Expansion, Strong Profit Prospects (Investor's Business Daily)
May-20-26 09:00AM	New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization (GlobeNewswire)
07:00AM	Loading…
May-14-26 07:00AM	Indivior to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-12-26 01:38PM	Medical Stock In Buy Zone After Breakout By Opioid-Addiction Treatment Maker (Investor's Business Daily)
May-04-26 07:00AM	Indivior Announces $175 Million Accelerated Share Repurchase (GlobeNewswire)
Apr-30-26 07:00AM	Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance (GlobeNewswire) +7.70%
Apr-24-26 11:00AM	Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder (GlobeNewswire)
Apr-16-26 02:30PM	Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse (GlobeNewswire)
Apr-09-26 07:00AM	Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th (GlobeNewswire)
Mar-31-26 09:00AM	New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities (GlobeNewswire) +5.91%
Mar-17-26 12:02PM	National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder (GlobeNewswire)
Mar-12-26 08:30PM	Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering (GlobeNewswire) -6.00%
07:00AM	Indivior Announces Proposed Convertible Senior Notes Offering (GlobeNewswire)
Mar-11-26 09:00AM	New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder (GlobeNewswire)
Mar-09-26 12:35PM	Implied Volatility Surging for Indivior Pharmaceuticals Stock Options (Zacks)
Feb-26-26 09:55AM	Indivior Pharmaceuticals Inc. (INDV) Tops Q4 Earnings and Revenue Estimates (Zacks)
09:16AM	Indivior Q4 Earnings Call Highlights (MarketBeat)
07:00AM	Loading…
07:00AM	Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-24-26 07:00AM	Indivior to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-19-26 09:45AM	Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
Jan-28-26 07:00AM	Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26?? (GlobeNewswire)
Jan-26-26 07:00AM	Indivior Announces Completion of Redomiciliation to the United States (GlobeNewswire)
Jan-21-26 07:17AM	Strength Seen in Ardelyx (ARDX): Can Its 15.0% Jump Turn into More Strength? (Zacks)
04:54AM	'Follow The Money,' Not The Tariff Noise, Says Expert, Spotlights This New S&P Data Center Cooling Stock Among Top Picks (Benzinga)
Jan-13-26 09:19AM	Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes (Zacks)
Jan-12-26 10:14AM	PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates (Zacks)
10:08AM	TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug (Zacks)
08:43AM	Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus (Zacks)
Jan-10-26 02:57PM	Indivior PLC (INDV) Announces Full-Year 2026 Financial Guidance (Insider Monkey)
Jan-09-26 11:46AM	AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations (Zacks)
Jan-08-26 11:09AM	GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug (Zacks)
08:57AM	4 Stocks Trading Near 52-Week High With Room to Rise Further (Zacks)
07:00AM	Indivior Provides Full-Year 2026 Financial Guidance and Business Update (GlobeNewswire)
Jan-07-26 11:45AM	FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug (Zacks)
09:53AM	OTLK Stock Crashes 67% in a Week: Here's What You Need to Know (Zacks)
Jan-06-26 11:53AM	ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH (Zacks)
Dec-30-25 10:32AM	Why This Top 100 Stock to Buy Is Getting Cheaper Even as It Soars Higher (Barchart)
Dec-22-25 07:00AM	Indivior Announces Inclusion in the S&P SmallCap 600 Index (PR Newswire)
06:00AM	2026 outlook: Small-cap biotechs may fill gaps on drug pipelines (Yahoo Finance Video)
Dec-17-25 11:30AM	New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations (PR Newswire)
Dec-05-25 05:49PM	CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Nov-20-25 04:01PM	Indivior Concludes Legacy U.S. Department of Justice Matter (PR Newswire)
Nov-19-25 09:21AM	Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference (PR Newswire)
Nov-07-25 08:37AM	4 Must-Buy Efficient Stocks to Enrich Your Portfolio in 2025 (Zacks)
Nov-06-25 03:25PM	3 Top Ranked Stocks that are the Best of the Best (Zacks)
Nov-03-25 08:00AM	Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine (PR Newswire) +6.23%
Oct-31-25 10:03AM	Indivior (INDV) Jumps to New High on Earnings Blowout, Optimistic Outlook (Insider Monkey)
Oct-30-25 04:22PM	Indivior PLC (INDV) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) +15.41%
02:18PM	Here's Why Indivior Stock Soared 15% Today (Motley Fool)
08:30AM	Indivior PLC (INDV) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:00AM	Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance (PR Newswire)
Oct-29-25 09:40AM	Indivior PLC (INDV) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-28-25 10:00AM	Indivior to Participate in the Stifel 2025 Healthcare Conference (PR Newswire)
Oct-23-25 09:21AM	Indivior PLC (INDV) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-16-25 04:04PM	Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th (PR Newswire)
Oct-15-25 08:00AM	Clinical Evidence Supports Rapid SUBLOCADE Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment (PR Newswire)
Oct-01-25 08:00AM	Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation (PR Newswire)
Sep-30-25 12:47PM	Indivior PLC (INDV) Raises 2025 Guidance After Q2 Revenue Hits $302M (Insider Monkey)
Sep-10-25 12:00PM	What Makes Indivior PLC (INDV) a Strong Momentum Stock: Buy Now? (Zacks)
Sep-09-25 11:57AM	Top 100 Stocks to Buy: Indivior Advances Into Top 50 on Momentum (Barchart)
Aug-20-25 12:00PM	Indivior to Participate in Upcoming Investor Events (PR Newswire)
Aug-06-25 09:36AM	Snap downgraded, Leidos upgraded: Wall Street's top analyst calls (The Fly)
Aug-05-25 12:00PM	All You Need to Know About Indivior (INDV) Rating Upgrade to Strong Buy (Zacks)
10:00AM	Best Momentum Stock to Buy for August 5th (Zacks)
06:16AM	New Strong Buy Stocks for August 5th (Zacks)
Aug-03-25 12:32PM	Indivior Plc (INDV) Jumps 22.8% on Impressive Earnings, Outlook (Insider Monkey)
Aug-01-25 01:23PM	Indivior (INDV) Extends Jump on 3rd Day with 16% Gain (Insider Monkey)
Jul-31-25 08:15AM	Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates (Zacks) +16.09%
07:00AM	Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance (PR Newswire)
Jul-30-25 09:43AM	Indivior PLC (INDV) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-28-25 10:06AM	Indivior PLC (INDV) Reinvents Leadership, Moves Listing to Nasdaq (Insider Monkey)
10:00AM	BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-25-25 02:00AM	Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained (PR Newswire)
Jul-24-25 10:00AM	Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-23-25 08:00AM	Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder (PR Newswire)
Jul-17-25 09:00AM	Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st (PR Newswire)
Jul-08-25 08:00AM	Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs (PR Newswire)
Jul-01-25 07:05AM	Indivior (INDV) Moves 5.7% Higher: Will This Strength Last? (Zacks)
Jun-30-25 07:00AM	Indivior Announces Inclusion in the U.S. Russell 2000 and 3000 Indexes (PR Newswire) +5.66%
Jun-27-25 05:45PM	IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Jun-24-25 04:12PM	Indivior Appoints Tony Kingsley to the Board of Directors (PR Newswire)
02:07PM	Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last? (Zacks)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
07:56AM	RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
Jun-20-25 03:01AM	Addex Therapeutics Ltd (ADXN) Q1 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Jun-19-25 09:00AM	Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users (PR Newswire)
Jun-05-25 05:08AM	Wise Plans to Shift Main Listing to US in Latest London Loss (Bloomberg)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anderson Woodrow D	Chief Accounting Officer	Aug 27 '26	Buy	35.69	1,500	53,535	27,638	Aug 27 04:00 PM
Anderson Woodrow D	Chief Accounting Officer	Aug 05 '26	Buy	36.28	1,500	54,420	26,138	Aug 05 04:52 PM
Heidbreder Christian	Chief Scientific Officer	Jul 10 '26	Sale	41.14	18,586	764,628	209,337	Jul 13 04:31 PM
Heidbreder Christian	Officer	Jul 10 '26	Proposed Sale	41.14	18,586	764,628		Jul 10 10:01 AM
Heidbreder Christian	Chief Scientific Officer	Jun 11 '26	Sale	38.06	18,586	707,383	227,923	Jun 12 04:10 PM
Heidbreder Christian	Officer	Jun 11 '26	Proposed Sale	38.06	18,586	707,383		Jun 11 11:20 AM
Preblick Ryan	Chief Financial Officer	Jun 08 '26	Sale	37.70	36,000	1,357,200	284,751	Jun 10 06:04 AM
Preblick Ryan	Officer	Jun 08 '26	Proposed Sale	37.70	36,000	1,357,200		Jun 08 01:58 PM
Ryan Barbara	Director	Mar 13 '26	Buy	31.09	8	249	5,724	Mar 13 04:25 PM
Kingsley Stuart A	Director	Mar 06 '26	Buy	31.86	940	29,953	5,582	Mar 11 09:54 AM
Ryan Barbara	Director	Mar 09 '26	Buy	32.56	31	1,009	5,716	Mar 11 08:12 AM
Ryan Barbara	Director	Jan 05 '26	Buy	35.39	775	27,429	1,963	Jan 07 01:51 PM
Humphreys Keith	Director	Jan 05 '26	Buy	35.39	775	27,429	5,802	Jan 07 01:50 PM
NINIVAGGI DANIEL A	Director	Jan 05 '26	Buy	35.39	775	27,429	16,923	Jan 07 01:49 PM
Stejbach Mark	Director	Jan 05 '26	Buy	35.39	775	27,429	16,847	Jan 07 01:48 PM
Wheadon David E.	Director	Jan 05 '26	Buy	35.39	1,771	62,680	14,395	Jan 07 01:47 PM

Supernus, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of treatments for patients living with central nervous system (CNS) diseases. Its portfolio includes treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company was founded in 2005 and is headquartered in Rockville, MD.

CEO & DirectorMr. Joseph J. Ciaffoni

Chief Financial OfficerMr. Ryan Preblick

Chief Scientific OfficerDr. Christian Heidbreder

Chief Legal OfficerMr. Jeffrey W. Burris J.D.

Chief Commercial OfficerMr. Patrick a. Barry

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Indivior Pharmaceuticals Inc

Upgrade your Finviz experience